Fabrice Lesage
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fabrice Lesage has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
A. Brunner
1 shared publicationA. Vezain
1 shared publication- Agathe Béranger
Université Paris Cité, Inserm, UMR1343, Pharmacologie et Évaluations des Thérapeutiques Chez l'Enfant et la Femme Enceinte, Paris, France
1 shared publication C.P. Hoffmann
1 shared publicationCarole Hennequin
Service de Biochimie Générale, Hôpital Necker Enfants Malades, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France
1 shared publicationEmmanuelle Bille
Service de Microbiologie, Hôpital Necker Enfants Malades, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France
1 shared publication
Latest Publications
- 18 June 2021
- Published by Springer Nature in Pediatric Drugs
- Vol. 23 (4) , 395-401
Assessment of the Effects of a High Amikacin Dose on Plasma Peak Concentration in Critically Ill Children
Objectives This study aimed to assess the incidence of amikacin plasma peak concentration (Cmax) below 60 mg·L−1 in critically ill children receiving an amikacin dosing regimen of 30 mg kg−1·day−1. Secondary objectives were to identify factors associated with low Cmax and to assess the incidence of acute kidney injury (AKI). Methods A retrospective observational study was performed in two French pediatric intensive care units. All admitted children who received 30 mg·kg−1 amikacin and had a Cmax measurement were eligible. Clinical and biological data, amikacin dose, and concentrations were collected. Results In total, 30 patients were included, aged from 3 weeks to 7 years. They received a median amikacin dosage of 30 mg kg−1·day−1 (range 29–33) based on admission body weight (BW), corresponding to 27 mg kg−1·day−1 (range 24–30) based on actual BW. Cmax was < 60 mg·L−1 in 21 (70%) children and none had a Cmax ≥ 80 mg·L−1. Among the 15 patients with a measured minimum inhibitory concentration (MIC), 13 (87%) had a Cmax/MIC ratio > 8. Univariate analysis showed that factors associated with Cmax < 60 mg·L−1 were high estimated glomerular filtration rate (p = 0.015) and low blood urea concentration (p = 0.001). AKI progression or occurrence was observed after amikacin administration in two (7%) and six (21%) patients, respectively. Conclusions Despite the administration of the maximal recommended amikacin dose, Cmax was below the pharmacokinetic target in 70% of our pediatric population. Further studies are needed to develop a pharmacokinetic model in a population of critically ill children to optimize target attainment.
- 18 June 2021
- Published by Springer Nature in Pediatric Drugs
- Vol. 23 (4) , 395-401
Assessment of the Effects of a High Amikacin Dose on Plasma Peak Concentration in Critically Ill Children
Objectives This study aimed to assess the incidence of amikacin plasma peak concentration (Cmax) below 60 mg·L−1 in critically ill children receiving an amikacin dosing regimen of 30 mg kg−1·day−1. Secondary objectives were to identify factors associated with low Cmax and to assess the incidence of acute kidney injury (AKI). Methods A retrospective observational study was performed in two French pediatric intensive care units. All admitted children who received 30 mg·kg−1 amikacin and had a Cmax measurement were eligible. Clinical and biological data, amikacin dose, and concentrations were collected. Results In total, 30 patients were included, aged from 3 weeks to 7 years. They received a median amikacin dosage of 30 mg kg−1·day−1 (range 29–33) based on admission body weight (BW), corresponding to 27 mg kg−1·day−1 (range 24–30) based on actual BW. Cmax was < 60 mg·L−1 in 21 (70%) children and none had a Cmax ≥ 80 mg·L−1. Among the 15 patients with a measured minimum inhibitory concentration (MIC), 13 (87%) had a Cmax/MIC ratio > 8. Univariate analysis showed that factors associated with Cmax < 60 mg·L−1 were high estimated glomerular filtration rate (p = 0.015) and low blood urea concentration (p = 0.001). AKI progression or occurrence was observed after amikacin administration in two (7%) and six (21%) patients, respectively. Conclusions Despite the administration of the maximal recommended amikacin dose, Cmax was below the pharmacokinetic target in 70% of our pediatric population. Further studies are needed to develop a pharmacokinetic model in a population of critically ill children to optimize target attainment.